Prognostic Value of N-Terminal pro-B-Type Natriuretic Peptide in Patients With Acute Coronary Syndromes Undergoing Left Main Percutaneous Coronary Intervention

Jaberg, Laurenz; Toggweiler, Stefan; Puck, Marietta; Frank, Michelle; Rufibach, Kaspar; Lüscher, Thomas F.; Corti, Roberto

doi:10.1253/circj.cj-11-0095

Cited by 12 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic value of natriuretic peptides has been established in many different scenarios. 16 17 Comorbidities, in particular COPD and CKD, have been found to be associated with worse prognosis in patients undergoing transcatheter aortic valve implantation. 18 …”

Section: Discussionmentioning

confidence: 99%

Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome

et al. 2014

Self Cite

View full text Add to dashboard Cite

ObjectiveAnalyse 2-year outcomes after MitraClip therapy and identify predictors of outcome.MethodsConsecutive patients (n=74) undergoing MitraClip therapy were included in the MitraSWISS registry and followed prospectively.ResultsA reduction of mitral regurgitation (MR) to ≤ mild was achieved in 32 (43%) patients and to moderate in 31 (42%) patients; 16/63 (25%) patients with initially successful treatment developed recurrent moderate to severe or severe MR during the first year and only 1 patient did so during the second year. At 2 years, moderate or less MR was more frequently present in patients with a transmitral mean gradient <3 mm Hg at baseline (73% vs 23%, p < 0.01) and in patients with a left atrial volume index (LAVI) <50 mL/m2 at baseline (86% vs 52%, p=0.03). More than mild MR post MitraClip, N-terminal probrain natriuretic peptide ≥5000 ng/L at baseline, chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) were associated with reduced survival.ConclusionsA mean transmitral gradient <3 mm Hg at baseline, an LAVI <50 mL/m2, the absence of COPD and CKD, and reduction of MR to less than moderate were associated with favourable outcome. Given a suitable anatomy, such patients may be excellent candidates for MitraClip therapy. Between 1 and 2 years follow-up, clinical and echocardiographic outcomes were stable, suggesting favourable, long-term durability of the device.

show abstract

Section: Discussionmentioning

confidence: 99%

Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that plasma levels of natriuretic peptides such as B-type natriuretic peptide (BNP) and NT-proBNP have a robust relationship with prognosis in patients with NSTE-ACS (10)(11)(12). Furthermore, previous studies have demonstrated that increased NT-proBNP levels in patients with NSTE-ACS are independently associated with the presence of more complex and severe coronary lesions (13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

The Association of Baseline N-terminal Pro-B-type Natriuretic Peptide With Short and Long-term Prognosis Following Percutaneous Coronary Intervention in Non-ST Segment Elevation Acute Coronary Syndrome With Multivessel Coronary Artery Disease: a Retrospective Cohort Study

Jiang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Although several studies have shown that N-terminal pro-B-type natriuretic peptide (NT-proBNP) is strongly correlated with coronary artery lesion complexity as well as prognosis in non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients, the prognostic value of NT-proBNP in patients with NSTE-ACS and multivessel coronary artery disease undergoing PCI remains unclear. This study aimed to reveal the relationship between NT-proBNP levels and prognosis among NSTE-ACS patients with multivessel coronary artery disease undergoing successfully percutaneous coronary intervention.Methods: We consecutively enrolled 1022 patients from January 2010 to December 2014. Patients with a diagnosis of NSTE-ACS with multivessel coronary artery disease and NT-proBNP levels were included. The primary outcome was in-hospital all-cause death. The 3-year follow-up all-cause death was also ascertained.Results: A total of 12 (1.2%) deaths occurred during hospitalization. The 4th quartile group of NT-proBNP (>1287 pg/ml) had the highest rate of in-hospital all-cause death (4.3%) (P<0.001). Logistic analyses revealed that increasing NT-proBNP was robustly associated with a higher risk of in-hospital all-cause death (adjusted OR: 2.86, 95% CI=1.16-7.03, P=0.022). NT-proBNP had a good ability to predict in-hospital all-cause death (AUC=0.888, 95% CI=0.834-0.941, P<0.001; cutoff: 1568pg/ml). The cumulative event analyses exhibited a statistically significant relationship between a higher level of NT-proBNP and a higher rate of the long-term all-cause death compared with a lower level of NT-proBNP (P< 0.0001).Conclusions: Increasing NT-proBNP is significant associated with a high risk of in-hospital and long-term all-cause death in NSTE-ACS patients with multivessel coronary artery disease who received percutaneous coronary intervention. NT-proBNP > 1568pg/ml was associated with all-cause, in-hospital death.

show abstract

“…B-type natriuretic peptide and its more stable counterpart, N-terminal pro-B-type natriuretic peptide (NT-proBNP), have shown great promise in this area, 6) covering a range of acute coronary syndromes. 7) At the same time, the emerging new peptides may also become clinically useful in the future. Stromal cell-derived factor-1 (SDF-1, also known as CXCL12), a constitutively expressed chemokine, has attracted much attention in the treatment of ischemic diseases.…”

mentioning

confidence: 99%

Role of Stromal Cell-Derived Factor-1 in Patients With Non-ST Elevation Acute Coronary Syndrome

et al. 2014

View full text Add to dashboard Cite

SummaryThe predictive value of stromal cell-derived factor-1 (SDF-1) has not been established in patients with non-ST elevation acute coronary syndrome (non-STEACS). A total of 678 consecutive patients with non-STEACS and moderate to high TIMI (Thrombolysis In Myocardial Infarction) risk scores were recruited. All patients underwent an early invasive strategy and then were followed-up for 18 months for clinical events. Left ventricular remodeling was assessed by echocardiography. Plasma concentrations of SDF-1 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were analyzed. SDF-1 level was an independent predictor of left ventricular remodeling (OR = 2.95, 95% CI = 2.02-4.30, P < 0.001). Cox regression analysis demonstrated that both SDF-1 and NT-proBNP levels were signifi cant independent predictors of death, myocardial infarction, or heart failure (HR = 2.45, 95% CI = 1.71-3.50, P < 0.001; HR = 3.71, 95% CI = 2.41-5.70, P < 0.001, respectively). The area under the ROC curves for SDF-1 (0.776) and NT-proBNP (0.817) were similar. The logistic model with both markers yielded a larger area under the ROC curve (0.862) than that of SDF-1 (P < 0.001) or NT-proBNP (P = 0.0001) alone. In patients stratifi ed by NT-proBNP (above 615.4 pmol/L), SDF-1 (above 2175.1 pg/mL) was associated with poorer outcome (P < 0.001). Findings were similar for death and heart failure as individual endpoints. In non-STEACS, higher SDF-1 levels were a signifi cant predictor of death, myocardial infarction, or heart failure independently of baseline clinical characteristics and NT-proBNP, and the combination of SDF-1 and NTproBNP signifi cantly improved risk stratifi cation. These data highlight the prognostic value of multiple, complementary biomarkers in non-ST elevation acute coronary syndrome. (Int Heart J 2014; 55: 219-227)

show abstract

Prognostic Value of N-Terminal pro-B-Type Natriuretic Peptide in Patients With Acute Coronary Syndromes Undergoing Left Main Percutaneous Coronary Intervention

Cited by 12 publications

References 30 publications

Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome

Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome

The Association of Baseline N-terminal Pro-B-type Natriuretic Peptide With Short and Long-term Prognosis Following Percutaneous Coronary Intervention in Non-ST Segment Elevation Acute Coronary Syndrome With Multivessel Coronary Artery Disease: a Retrospective Cohort Study

Role of Stromal Cell-Derived Factor-1 in Patients With Non-ST Elevation Acute Coronary Syndrome

Contact Info

Product

Resources

About